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Introduction: O6-methylguanine-methyltransferase (MGMT) promoter methylation and
isocitrate dehydrogenase (IDH) mutation status are important prognostic factors for
patients with glioblastoma. There are conflicting reports about a differential topographical
distribution of glioblastoma with vs. without MGMT promoter methylation, possibly
caused by molecular heterogeneity in glioblastoma populations. We initiated this study
to re-evaluate the topographical distribution of glioblastoma with vs. without MGMT
promoter methylation in light of the updated WHO 2016 classification.
Methods: Preoperative T2-weighted/FLAIR and postcontrast T1-weighted MRI scans
of patients aged 18 year or older with IDH wildtype glioblastoma were collected.
Tumors were semi-automatically segmented, and the topographical distribution between
glioblastoma with vs. without MGMT promoter methylation was visualized using
frequency heatmaps. Then, voxel-wise differences were analyzed using permutation
testing with Threshold Free Cluster Enhancement.
Results: Four hundred thirty-six IDH wildtype glioblastoma patients were included;
211 with and 225 without MGMT promoter methylation. Visual examination suggested
that when compared with MGMT unmethylated glioblastoma, MGMT methylated
glioblastoma were more frequently located near bifrontal and left occipital periventricular
area and less frequently near the right occipital periventricular area. Statistical analyses,
however, showed no significant difference in topographical distribution between MGMT
methylated vs. MGMT unmethylated glioblastoma.
Conclusions: This study re-evaluated the topographical distribution of MGMT
promoter methylation in 436 newly diagnosed IDH wildtype glioblastoma, which is
the largest homogenous IDH wildtype glioblastoma population to date. There was no
statistically significant difference in anatomical localization between MGMT methylated
vs. unmethylated IDH wildtype glioblastoma.
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INTRODUCTION
Patients with glioblastoma have a poor prognosis with a median
overall survival of 15 months, despite standard of care consisting
of safe, and maximal surgical resection followed by chemo-
and/or radiotherapy (1). This prognosis varies based on factors
such as age, Karnofsky Performance Status, extent of resection,
and molecular markers, in particular isocitrate dehydrogenase
(IDH) mutation and O6-methylguanine-methyltransferase
(MGMT) promoter methylation status (2).
MGMT is a DNA repair enzyme, which is expressed by
the MGMT gene located on chromosome 10q26. Promoter
methylation of this gene reduces MGMT protein expression
and consequently decreases DNA repair and increases alkylating
chemotherapy induced tumor death. Therefore, patients with
MGMT methylated glioblastoma are more sensitive to neo-
adjuvant temozolomide than those without MGMT methylated
glioblastoma. MGMT is methylated in ∼50% of patients with
newly diagnosed glioblastoma (3).
There are conflicting results in the published literature on a
possible differential topographical distribution of glioblastoma
with vs. without MGMT promoter methylation (4). Ellingson
et al. suggested that when compared with those without MGMT
promoter methylation, glioblastoma with methylation are more
frequently located in the left temporal lobe and less frequently
in the right temporal lobe (5). However, other studies found
the reverse lateralization pattern (6) or did not find any
lateralization at all (7–9). These conflicting results could be
ascribed to heterogeneity of molecular subtypes of glioblastoma
in the studied populations, for instance when IDH wildtype
glioblastoma are mixed with the genetically, and prognostically
distinct IDH mutated glioblastoma, or to variation in statistical
methods that were used across studies. Therefore, the question
whether glioblastoma with vs. without MGMT promoter
methylation have a different anatomical localization remains
unanswered. In light of the updated WHO 2016 classification
(10), a molecularly homogenous glioblastoma population must
be used to re-evaluate the topographical distribution of MGMT
methylated vs. unmethylated glioblastoma.
Therefore, we have initiated this study to re-evaluate the
topographical distribution of glioblastoma with and vs. without
MGMT promoter methylation in the largest homogenous IDH
wildtype glioblastoma population to date.
METHODS
Patient Inclusion
All consecutive patients aged 18 years or older newly diagnosed
with a contrast-enhancing and histopathologically confirmed
glioblastoma IDH wildtype who underwent tumor resection or
biopsy between January 2011 and May 2018 at the Erasmus
MC, University Medical Center Rotterdam, or Haaglanden MC
were retrospectively included in this study. Patients were eligible
if preoperative T2-weighted/fluid-attenuated inversion recovery
Abbreviations: FLAIR, fluid-attenuated inversion recovery; IDH, isocitrate
dehydrogenase; MGMT, O6-methylguanine-methyltransferase.
(FLAIR) and postcontrast T1-weighted MRI scans as well as
molecular data on IDH mutation and MGMT methylation
status were available. Recurrent glioblastoma or confirmed IDH
mutated glioblastoma were excluded. The study design was
approved by the Medical Ethical Committee of Erasmus MC
and Haaglanden MC. The study was performed in accordance
with the 1964 Helsinki Declaration and its later amendments or
comparable ethical standards.
Image Acquisition, Tumor Segmentation,
and Registration
From clinical preoperative MRI scans, which were obtained
according to clinical brain tumor protocols on either a 1.5T or
3.0T scanner, T2-weighted/FLAIR and postcontrast T1-weighted
images were collected. For glioblastoma segmentation, we
first imported both the postcontrast T1-weighted and T2-
weighted/FLAIR scans into BrainLab (BrainLab, Feldkirchen,
Germany, version 2.1.0.15). We semi-automatically segmented
all tumor-related contrast-enhancement (including the central
necrotic part, if present) using the SmartBrush tool in Brainlab
Elements and manually adapted the segmentation if needed. We
then used the T2-weighted/FLAIR scan to semi-automatically
segment all tumor-related non-enhancing hyperintense
abnormalities (extra-lesional hemorrhage was excluded).
All tumor segmentations were then registered to the Montreal
Neurological Institute (MNI) International Consortium for Brain
Mapping 152 non-linear atlas. The postcontrast T1-weighted
scans were registered to the T1-weighted atlas and the T2-
weighted/FLAIR scans to the T2-weighted atlas. Registration
was done using SimpleElastix (version 72b7e81), based on a
mutual information metric using an affine registration (11).
The resulting transformation parameters were used to transform
the 3D segmentations to the atlas space. Registration results
were visually checked to ensure that for all cases, the registered
masks lay entirely within the brain mask of the atlas. No
adjustments were made to the initial registration settings for
individual patients. We created voxel-wise frequency maps for
all glioblastoma combined, and frequency difference maps of
glioblastoma with vs. without MGMT promoter methylation.
Molecular Analysis
Tumor tissue samples were obtained from patients through
surgical resection or biopsy. Histopathological examination
was performed by neuropathologists. DNA was extracted from
microdissected FFPE tissue fragments by proteinase K digestion
for 16 h at 56◦C in the presence of 5% Chelex 100 resin
and used after inactivation of proteinase K and removal of
cell debris and the Chelex resin. IDH mutational analysis was
assessed with Sanger sequencing and targeted next generation
sequencing (NGS) analysis. Sanger sequencing of PCR-amplified
fragments from IDH1 and IDH2 mutational hot spots was
essentially performed as previously described (12). M13-tailed
primers for PCR amplification of IDH1 codon 132 were
forward 5′- TCTTCAGAGAAGCCATTAT-3′ and reverse 5′-
GCAAAATCACATTATTGCCAAC-3′, for IDH2 codon 140,
forward 5′-GGCTGCAGTGGGACCACTAT-3′ and reverse 5′-
TTGGTCCAGCCAGGGACTAG-3′, and for IDH2 codon 172,
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forward 5′- ACATCCTGGGGGGGACTGTC-3′ and reverse
5′- GACAAGAGGATGGCTAGGCG-3′. The M13-tail for the
forward primers was: 5′- TGTAAAACGACGGCCAGT-3′ and
for the reverse primers: 5′-CAGGAAACAGCTATGACC-3′.
After initial denaturation at 95◦C for 3min, 35 cycles of 95◦C for
15 s, 60◦C for 15 s, and 72◦C for 15 s were performed, followed
by 7min at 72◦C. Subsequent sequence analyses of the PCR
products was carried out with M13 forward and reverse primers
on a 3730 XL Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA).
Targeted NGS was performed by semiconductor sequencing
with the Ion Torrent platform using supplier’s materials and
protocols (Thermo Fisher Scientific) with a dedicated panel for
detection of glioma-specific aberrations, including IDH1 and
IDH2 hot spot mutations essentially as previously described (13).
Library and template preparations were performed consecutively
with the AmpliSeq Library Kit 2.0-384 LV and the Ion PGM
Template OT2 200 kit. Sequencing was performed with the
Ion PGM Sequencing 200 Kit v2 on an 318v2 chip with the
PGM system. Data were analyzed with the Torrent variant caller
(Thermo Fisher Scientific), and variants were annotated in a local
Galaxy pipeline using ANNOVAR. Data were collected during
several years using different glioma panels. Sequenced areas of
IDH1 codon 132 and IDH2 codons 140 and 172 are given in the
supplementary data of Dubbink et al. (13).
MGMT promoter methylation status was assessed by
methylation-specific PCR essentially as described by Esteller
et al. (14) Bisulfite conversion and subsequent purification
are performed with the EZ DNA Methylation-Lightning
Kit (Zymo Research) according to the supplier’s protocol.
Methylation-specific PCR was performed with primers specific
for either methylated or the modified unmethylated DNA.
Converted primer sequences for unmethylated DNA were
forward 5′-TTTGTGTTTTGATGTTTGTAGGTTTTTGT-3′
and reverse 5′-AACTCCACACTCTTCCAAAAACAAAACA-
3′, and for the methylated reaction, forward 5′-
TTTCGACGTTCGTAGGTTTTCGC-3′ and reverse
5′-GCACTCTTCCGAAAACGAAACG-3′. PCR was performed
after initial denaturation at 96◦C for 5min, 40 cycles of 92◦C
for 45 s, 59◦C for 65 s, and 72◦C for 45 s, followed by 7min
at 72◦C. Five microliters of each 15 µl methylation-specific
PCR product was loaded onto a 1.5% agarose gel stained with
GelRed (Biotium) and examined under ultraviolet illumination.
SW48 cell line DNA and tonsil DNA was used as a positive
control for methylated and unmethylated alleles of MGMT,
respectively. Controls without DNA were used for each set of
methylation-specific PCR assays.
Statistical Analysis
We first tested the differences between preoperative enhancing
and non-enhancing tumor volumes as well as their ratio with the
Kruskal-Wallis test.Wemapped the anatomical localization of all
MGMT methylated and unmethylated glioblastoma by iterating
over all voxels in the MNI atlas and counting the number of
tumor frequencies for each group in each voxel. To test for
differences in spatial distribution between glioblastoma with vs.
without MGMT promoter methylation, we assessed the cluster-
wise significance at the voxel-level between distributions, using
permutation testing with Threshold Free Cluster Enhancement
(15) in the software package “FSL Randomise” (version 5.0.9,
using 10,000 permutations) (16). We also performed the same
analysis with correction for age as a potential confounder by
determining age for each patient at the time of the MRI scan.
We then calculated the difference between each patient’s age and
the average age of all patients included in the study, which was
added to the experimental setup for FSL Randomise. Threshold
Free Cluster Enhancement corrects p-values for the family-wise
error in testing multiple voxels, considering a corrected p < 0.05
as statistically significant.
RESULTS
In total, 769 patients with newly diagnosed, contrast enhancing
glioblastoma were screened, of whom we excluded 333 patients:
22 were excluded due to IDH mutation and 311 were
excluded due to insufficient or missing molecular data on
IDH mutation or MGMT methylation status. Final analysis
included 436 patients with IDH wildtype glioblastoma (see
flowchart, Supplementary Material); 211 with and 225 without
MGMT promoter methylation. Three hundred forty patients had
undergone a surgical tumor resection and 96 a diagnostic biopsy.
In all patients, preoperative postcontrast T1-weighted MRI scans
were available; in 90 patients, T2-weighted FLAIR scans, and in
346 patients T2-weighted scans were available. When compared
with MGMT unmethylated glioblastoma, MGMT methylated
glioblastoma had a significantly higher ratio of non-enhancing vs.
contrast-enhancing volume [2.09 (inter quartile range 2.6) and
2.5 (inter quartile range 3.3), p= 0.045, respectively]. Patient and
tumor characteristics are further presented in Table 1.
Topographical Mapping of 436 IDH
Wildtype Glioblastoma
For visual inspection, heatmaps based on postcontrast T1-
weighted and T2-weighted/FLAIR segmentations were created
for all 436 patients combined (Figures 1, 2), as well as
frequency difference maps between MGMT methylated vs.
unmethylated glioblastoma (Figure 3). Visual inspection of maps
in Figure 1 suggests that glioblastoma were most frequently
located in the right temporal, insular, and parietal area, and
near the periventricular area both frontally and occipitally. Visual
inspection of Figures 2, 3 indicates that when compared with
MGMT unmethylated glioblastoma, methylated glioblastoma
were more frequently located near bifrontal and left occipital
periventricular area (up to 6.5% frequency difference) and less
frequently near the right occipital periventricular area (up to
9.1% frequency difference).
To test whether this difference was statistically significant,
voxel-wise analyses of both the postcontrast T1-weighted and
T2-weighted/FLAIR segmentation heatmaps were performed.
Although statistical analysis of the postcontrast T1-weighted
scans marked a region near the right occipital periventricular
area as a potentially discriminating area between MGMT
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TABLE 1 | Patient and tumor characteristics.
Characteristics n %
All patients 436 100
Sex
Male 276 63.3
Female 160 36.7
Age
≤65 227 52.1
>65 209 47.9
Mean, years (SD) 61.5 (16.2)
Karnofsky performance status
≤70 142 32.6
>70 294 67.4
Mean (SD) 80 (12.5)
Preoperative MRI scans
T1 postcontrast 436 100
T2-weighted 346 79.4
T2-weighted FLAIR 90 20.6
Neurosurgical procedure
Resection 340 78.0
Biopsy 96 22.0
Preoperative volume,
median cm3 (IQR)
MGMT promoter p-value
Methylated
211 (48.4%)
Unmethylated
225(51.6%)
Contrast-enhancing 30.1 (39.5) 35 (45.8) 0.130
Non-enhancing 75.5 (105.0) 65.5 (84.2) 0.338
Non-enhancing/contrast-
enhancing ratio
2.5 (3.3) 2.09 (2.6) 0.045
SD, standard deviation; IQR, interquartile range; CE, contrast enhancement; FLAIR
fluid-attenuated inversion recovery.
methylated vs. unmethylated glioblastoma, this difference
was not statistically significant (Figure 4, together with
corresponding p-values). This figure in fact shows that not
any statistically significantly discriminating brain area between
MGMT methylated and unmethylated glioblastoma could be
found (p < 0.05). This result did not change after an additional
analysis with correction for age as potential confounding factor.
Scroll-through video clips for visual inspection of all topographic
maps are publicly available as Supplementary Material.
DISCUSSION
This study voxel-wise analyzed postcontrast T1-weighted
and T2-weighted/FLAIR heatmaps and showed that there
was no statistically significant difference in anatomical
localization between MGMT methylated vs. unmethylated
IDH wildtype glioblastoma.
The primary reason to initiate this study was to re-evaluate
the anatomic localization ofMGMTmethylated vs. unmethylated
glioblastoma in light of the updated WHO 2016 classification
era following conflicting reports on this topic (4). Ellingson
et al. (17) reported that glioblastoma with MGMT methylation
were lateralized to the left hemisphere (temporal lobe) and that
those without were lateralized to the right hemisphere (17),
which was in line with their previous article (2012) and in
which they included a substantial portion of their previously
studied glioblastoma population (5). However, in contrast to
these findings, there are also studies that found the reverse
pattern of hemispheric lateralization, in which glioblastoma with
MGMT methylation were located more frequently in the right
hemisphere, while those without MGMT methylation lateralized
to the left hemisphere (6). Additionally, there are conflicting
reports on lobar distribution, in which glioblastoma with
MGMTmethylation were more frequently located in the parietal
and occipital lobes, while those without were located more
frequently in the temporal lobes (8). A recent study suggested
after qualitative analyses that subventricular zones were more
frequently spared with MGMT methylated glioblastoma, but
found no difference in hemispheric lateralization between
glioblastoma with and without MGMT promoter methylation
(9). Finally, there are also studies that report no differences
in localization between glioblastoma with and without MGMT
methylation (7, 18) in concordance with the findings of our study.
These conflicting results in the literature can potentially be
ascribed to two methodological issues. First, inconsistencies may
arise from variations in glioblastoma patient populations across
studies, many of which were performed in the pre-WHO 2016
classification era when the impact of molecular subtyping of
glioblastoma according to IDH mutation status was less of a
consideration (10). Ellingson et al. (17) included a series of
507 de novo glioblastoma with mixed IDH subtypes, including
366 IDH wildtype, 34 IDH mutated glioblastoma, and also
107 glioblastoma without data on IDH mutation status (17).
Moreover, the majority of the studies did not report the IDH
mutation status of included glioblastoma (5, 6, 8, 18).
Mixing molecular subtypes or not knowing IDH mutation
status of glioblastoma is undesirable when assessing
topographical distribution of molecular subtypes (10), since
it is now known that IDH mutated glioblastoma represent
a distinct molecular subtype of glioblastoma from a distinct
precursor lesion which have a predominantly frontal lobe
involvement when compared with IDH wildtype glioblastoma
(19). This topographic link between IDH mutation and
MGMT methylation was also suggested by Ellingson et al. (17)
by demonstrating that IDH mutated and MGMT methylated
glioblastoma were indeed more frequently localized in the frontal
lobe (17). This has not only been demonstrated in glioblastoma
but also in non-contrast enhancing low grade glioma in which
IDH mutated low grade glioma (both oligodendroglioma
and astrocytoma) were more frequently located in the frontal
lobes, while non-contrast enhancing IDH wildtype astrocytoma
were more frequently located in the basal ganglia of the right
hemisphere (20). This topographical link thus suggests IDH
mutation status as a (confounding) factor between MGMT
methylation status and localization. Therefore, studies must
be conducted based on homogeneous tumor populations with
respect to IDH mutational status. This hypothesis was recently
supported by Roux et al., who assessed a homogenous IDH
Frontiers in Oncology | www.frontiersin.org 4 May 2020 | Volume 10 | Article 596
Incekara et al. Atlas of 436 GBM
FIGURE 1 | Heatmaps of all 436 isocitrate dehydrogenase (IDH) wildtype glioblastoma.
FIGURE 2 | Heatmaps of O6-methylguanine-methyltransferase (MGMT) methylated (N = 211) and unmethylated (N = 225) glioblastoma.
Frontiers in Oncology | www.frontiersin.org 5 May 2020 | Volume 10 | Article 596
Incekara et al. Atlas of 436 GBM
FIGURE 3 | Frequency difference maps between MGMT methylated (N = 211) and unmethylated (N = 225) glioblastoma.
FIGURE 4 | P-value maps of MGMT methylated (N = 211) and unmethylated (N = 225) glioblastoma.
wildtype glioblastoma population (n = 392) and found no
difference in localization between glioblastoma with and without
MGMTmethylation, in line with our study (21).
Second, the conflicting results in the literature may arise
from different statistical methods that were used across
studies. Studies often investigated the anatomic localization of
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glioblastoma with and without MGMT promoter methylation
with visual examination, qualitatively, without a statistical,
voxel-wise quantitative analysis (7–9, 18). Ellingson et al. (17)
used frequency difference maps to demonstrate that MGMT
methylated glioblastoma were more frequently localized in the
left temporal lobe (17). Using similar frequency difference
maps, we also found topographical differences, which indicated
that when compared with MGMT unmethylated glioblastoma,
MGMT methylated glioblastoma were more frequently localized
near bifrontal and right occipital periventricular area and
less frequently near the right occipital periventricular area.
However, we showed that these apparent differences did not
survive rigorous statistical testing. Ellingson et al. report the
use of “Analysis of Differential Involvement” for their statistical
analysis, which is based on the Fisher exact test (5). We
used “FSL randomise,” which is different from the Fisher
exact test because it does not make any assumptions about
the underlying distribution of the variables (16). Another
methodological difference can be found in the correction for
multiple comparisons. Ellingson et al. used random permutations
based on Bullmore et al. instead of the more recently proposed
and widely accepted method of doing random permutations
employed in “FSL randomise” based on Smith and Nichols (15)
and Bullmore et al. (22). Furthermore, the method by Bullmore
et al. requires a user-defined threshold for clustering, which can
impact the results substantially (22). Instead, we used “Threshold
Free Cluster Enhancement,” which does not require thresholding
to determine the clusters, and which has been shown to have a
higher sensitivity compared to other methods (15). Our stringent
methodology of rigorous statistical testing and applying new
insights in glioblastoma molecular subtyping to a large studied
patient population are the strengths of our study.
LIMITATIONS
Themain limitation of this study is its retrospective design, which
may have introduced selection and confounding biases. Selection
bias may occur when patients who receive diagnostic biopsies
are excluded from analysis, since these tumors are often large,
multifocal, located deep within the basal ganglia, or crossing
midline. This may skew the results on tumor localization of
glioblastoma, which is our main outcome. We have therefore
attempted to limit this bias first by consecutive inclusion of all
glioblastoma patients operated upon between 2011 and 2018 in
our cohort, including diagnostic biopsies. In addition, it is known
that tumor localization is associated with IDH mutation status,
with IDH mutated tumors located more frequently in the frontal
lobes, as mentioned earlier (19). Since IDH mutation status is
both associated with tumor localization and MGMTmethylation
status, it may function as a confounding factor.We therefore have
also attempted to limit this potential bias by excluding all IDH
mutated tumors. Another limitation is that we included patients
from two medical centers from a period of over seven years.
This introduced variation of MRI scan protocols such as magnet
strength, voxel size, and slice thickness, which consequently may
have negatively influenced registration accuracy and anatomical
localization. Such registration inaccuracies can however be
considered minor relative to the size of the tumor, and it is
therefore unlikely that our results were significantly impacted
by scanner variations. Additionally, tumor volume assessment
on these MRI scans were performed by one observer without
confirmation of a second, independent assessor. This may have
introduced some degree of information bias. We have attempted
to limit this bias during volumetric assessment by blinding
the assessor for patients’ clinical and molecular characteristics.
Also, it is known that both the inter- and intraobserver
agreement for preoperative tumor volumes in glioblastoma
is relatively high, while small variations in segmentation will
probably have only a very limited effect on determining gross
tumor localization (23). Finally, it should be noted that the
known intertest variability is a limitation of MGMT analyses,
as assays used in other studies may produce slightly different
MGMT methylation results (24). This may partially explain the
variety in the proportion of MGMT methylated tumors reported
in literature.
To conclude, in the largest homogenous IDH wildtype
glioblastoma population to date, we showed that visual
appearance of differences could not be confirmed with
rigorous voxel-wise statistical testing and thus that there is
no statistical difference in anatomical localization between
IDH wildtype glioblastoma with vs. without glioblastoma
promoter methylation.
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